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ExosomesShort collagen-like peptides (CLPs) are being proposed as alternatives to full-length collagen for use in
tissue engineering, on their own as soft hydrogels, or conjugated to synthetic polymer for mechanical
strength. However, despite intended clinical use, little is known about their safety and efficacy, mecha-
nism of action or degree of similarity to the full-length counterparts they mimic. Here, we show the func-
tional equivalence of a CLP conjugated to polyethylene glycol (CLP-PEG) to full-length recombinant
human collagen in vitro and in promoting stable regeneration of corneal tissue and nerves in a pre-
clinical mini-pig model. We also show that these peptide analogs exerted their pro-regeneration effects
through stimulating extracellular vesicle production by host cells. Our results support future use of
CLP-PEG implants for corneal regeneration, suggesting the feasibility of these or similar peptide analogs
in clinical application in the eye and other tissues.
Statement of significance
Although biomaterials comprising full-length recombinant human collagen and extracted animal colla-
gen have been evaluated and used clinically, these macromolecules provide only a limited number of
functional groups amenable to chemical modification or crosslinking and are demanding to process.
Synthetic, customizable analogs that are functionally equivalent, and can be readily scaled-up are there-
fore very desirable for pre-clinical to clinical translation. Here, we demonstrate, using cornea regenera-
tion as our test bed, that collagen-like-peptides conjugated to multifunctional polyethylene glycol
(CLP-PEG) when grafted into mini-pigs as corneal implants were functionally equivalent to recombinant
human collagen-based implants that were successfully tested in patients. We also show for the first time
that these materials affected regeneration through stimulation of extracellular vesicle production by
endogenous host cells that have migrated into the CLP-PEG scaffolds.
 2018 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The current global need for replacement organs and tissues
requires numbers that far exceed the donor supply. Artificial
organs as alternatives can potentially save and improve the quality
of lives of patients. The macromolecules of the extracellular matrix
(ECM), specifically collagen, have been extensively tested for use as
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will stimulate regeneration, recapitulating their role in organogen-
esis during embryogenesis. ECM-derived or inspired biopolymers
ranging from decellularized tissues/organs to fabricated constructs
are being evaluated or used clinically for promoting regeneration.
However, natural ECM macromolecules like collagen are large
and difficult to extract and process or modify, and are heteroge-
neous and source-dependent. While the use of recombinantly pro-
duced human collagen eliminates heterogeneity, these are still
large macromolecules that require significant processing. This
makes short peptide analogs that are readily prepared, easily cus-
tomized and scaled-up, very attractive ECM alternatives for regen-
erative medicine. Several in vitro and in vivo studies have reported
that such short ECM-mimicking peptides can stimulate regenera-
tion in a range of organ systems including bone and spinal cord
[2,3]. However, despite their great potential, little is known about
their safety and efficacy, mechanism of action, or functional equiv-
alence to their clinically evaluated full-length counterparts.
Here, we tested under pre-clinical conditions in mini-pigs, the
safety and efficacy of a collagen-like peptide (CLP) conjugated to
an inert but mechanically tougher multifunctional polyethylene
glycol (PEG) to emulate the function of a collagen-based implant
[4] for promoting regeneration, using the cornea as a model sys-
tem. The cornea is the transparent front of the eye and major
refractive surface for focusing light to the retina for vision. Its
superficial location and transparency allow easy access and real-
time visualization of cell-biomaterial interactions. A diseased or
damaged cornea with permanent transparency loss results in
blindness. The conventional treatment is transplantation with
donated human corneas. However, like other organs, cornea trans-
plantation suffers from a severe global shortfall, with an estimated
12.7 million patients worldwide awaiting transplantation, or only
one out of every 70 patients being transplanted [5]. The trans-
parency, accessibility plus the pressing medical need make the cor-
nea an attractive model tissue.
We previously used full-length recombinant human collagen
type III (RHCIII) to fabricate implants that successfully stimulated
stable regeneration of the human cornea, an organ that does not
normally regenerate on its own. Corneal implants comprising
RHCIII only and RHCIII incorporating 2-methacryloyloxyethyl
phosphorylcholine (MPC), a synthetic lipid-polymer that can sup-
press inflammation, [6] were evaluated clinically [7–9]. They
respectively promoted stable corneal regeneration without contin-
ual immunosuppression in 10 conventional transplantation
patients [7,8] and three patients diagnosed as being at high-risk
for rejection of donor corneas [9]. Although the use of RHCIII
instead of extracted animal collagen mitigates potential source
heterogeneity, xenogeneic reaction, or risk of pathogen transmis-
sion [10,11], RHCIII replicates full-length collagen, which, is large
and relatively difficult to chemically tailor or process, unlike short
peptides. In this study, we compared in detail the safety, efficacy,
and mechanism of promoting regeneration of corneal implants
made from CLP-PEG to control implants made from clinically
tested RHCIII-MPC in vitro, and in rabbit and mini-pig animal mod-
els. Successful testing in a simple organ system like the cornea will
allow for the extension to more complex applications such as skin
and heart, as we have shown with collagen after minimal modifi-
cation [12–14].2. Materials and methods
2.1. Hydrogel implants
CLP-PEG and RHCIII-MPC implants were prepared as previously
described [4,15]. Briefly, CLP comprising Cys-Gly-(Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)4, was synthesized (UAB Feren-
tis, Vilnius, Lithuania) and conjugated to a 40 kDa 8 arm PEG-
maleimide (Creative PEG Works, NC, USA) by continually stirring
in ddH2O at pH 4.5 for 2 days at a molar ratio of 32:1 and then dia-
lyzed against distilled water using 12–14 kDa MWCO tubing for 2–
3 days before lyophilization. 500 mg of 12% (w/w) CLP-PEG solu-
tion prepared was crosslinked with EDC and NHS at molar equiva-
lents of CLP-PEG-NH2:EDC (1:2) and at equal molar ratio of EDC:
NHS. All the reagents were moulded into flat sheets or cornea-
shaped implants [4].
RHCIII-MPC implants were fabricated by mixing 18% (w/w)
aqueous solution RHCIII (FibroGen Inc., San Francisco, CA) with
2-methacryloyloxyethyl phosphorylcholine (MPC, Paramount Fine
Chemicals Co. Ltd., Dalian, China) and poly(ethylene glycol) diacry-
late (PEGDA, Mn 575, Sigma-Aldrich) in a morpholinoethane sul-
fonic acid monohydrate (MES, Sigma-Aldrich, MO) buffer. The
ratio of RHCIII:MPC was 2:1 (w/w) and PEGDA: MPC was 1:3
(w/w). Polymerization initiators ammonium persulphate (APS;
Sigma-Aldrich) and N,N,N,N-tetramethylethylenediamine (TEMED,
Sigma-Aldrich) at ratios of APS:MPC = 0.03:1 (wt/wt), APS:TEMED
(wt/wt) = 1:0.77, crosslinker, N-(3-dimethylaminopropyl)-N’-ethyl
carbodiimide (EDC; Sigma-Aldrich) and its co-reactant,
N-hydroxysuccinimide (NHS; Sigma-Aldrich) was then mixed in.
The resulting solution was dispensed into cornea-shaped moulds
and cured [15].
After demoulding, all hydrogels were washed thoroughly with
phosphate buffered saline (PBS) and placed into vials of aseptic
PBS containing 1% chloroform, which were sealed to maintain
sterility.2.2. Physical and mechanical characterization
Flexure tests, physical appearance and light transmittance mea-
surements were carried out following the established quality con-
trol (QC) protocols [15,16]. The same tests were used to determine
stability of the implant after storage for a minimum of 12 months
at 4 C. Qualitative analysis included Fourier Transform Infrared
(FTIR) spectroscopy to evaluate the chemical integrity of the com-
ponents within the hydrogel implants after 12 months of storage.
The most relevant amide IR vibrations for CLP were used for this
purpose: Amide A, B, I and II [17]. Samples were dried for 3 days.
Measurements were carried out in a Nicolet 6700 FTIR spectrome-
ter equipped with a Smart iTR Attenuated Total Reflectance (ATR)
sampling accessory with 4 cm1 resolution; a total of 64 individual
spectra were collected for each sample. Representative spectra
were collected in a Nicolet iS5 FT-IR spectrometer equipped with
an iD7 ATR accessory using 300 individual spectra with 4 cm1
resolution.
Collagenase from Clostridium histolyticum (Sigma-Aldrich, MO,
USA), at 5 U/ml in 0.1 M Tris-HCl buffer containing 5 mM CaCl2
was used to evaluate the stability of hydrogels as previously
described [4]. Briefly, samples were weighed after blotting off sur-
face water at different time points to determine the rate of loss of
mass. The percentage of residual weight was calculated using the
following equation: Residual mass % = Wt/Wo%, where Wt is the
weight of hydrogel at a certain time point and Wo is the initial
weight of the hydrogel.
Denaturation temperature of the CLP-PEG hydrogels was deter-
mined using a Q2000 differential scanning calorimeter (TA Instru-
ments, New Castle, DE), with a temperature range from 8 to 200 C
at a scan rate of 5 C min1. Hydrogels (approximately 3 to –5 mg)
were placed in an aluminum pan after removing the surface water.
The pan was then hermetically sealed to make an airtight condi-
tion. Denaturing temperature was calculated from the curve of
heat flow versus temperature increase.
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19 C at a wavelength of 589 nm, using a bench-top Abbe 60 series
Refractometer (Bellingham and Stanley, London, UK) that was cal-
ibrated against a silica test plate of known refractive index.
For rheology, three, six-month old female New Zealand White
rabbits, were implanted with CLP-PEG hydrogels, 6 mm in diame-
ter, 350 mm thick by anterior lamellar keratoplasty after ethical
permission from local ethical committee, Linköpings Djurförsökse-
tiska Nämnd and in compliance with Swedish Animal Welfare
Ordinance and Animal Welfare act. At 6 months post-operation,
the rabbits were euthanized. Operated corneas and their unoper-
ated contralateral corneas were dissected. Oscillatory rheology
was performed on a discovery hybrid rheometer, DHR-2 from TA
instruments (Sweden). Circular disks of 8 mm diameter were cut
out from the excised rabbit eyes (operated and unoperated) using
a biopsy punch. All experiments were performed using 8 mm
diameter parallel-plate geometry and at 35 C under axial force
of 170mN to ensure firm gripping. All frequency sweep experi-
ments were performed using shear strain amplitude of 0.27%.
2.3. In vitro toxicology and biocompatibility
2.3.1. VitotoxTMASSAY
Observations on cytotoxicity and genotoxicity were done with
the previously described VitotoxTM protocol (Gentaur, Belgium)
[18]. In brief, VitotoxTM is closely related to the Ames test and is
regarded as a highly sensitive technique for cytotoxic and geno-
toxic screening. A diluted TA104 RecN2-4 (Genox) and TA104
(Cytox) Salmonella typhimurium suspension (1/10 dilution) was
added to homogenized RHCIII-MPC and CLP-PEG. S9 was added
to the designated +S9 cultures to test the genotoxic effects of the
metabolites of the compounds. The bacterial suspensions were
then incubated, shaking at 36 C, and the luminescent signal was
measured every 5 mins for 4 h. Signal to Noise ratio (S/N value)
were recorded for Genox and Cytox respectively. Scaffolds were
soaked in 0.1 M PBS for 24 h and homogenized in a tissue grinder
for 5 min and sonicated for 40 min. Three concentrations of the
resulting homogenate were tested (100% (undiluted), 10% (1/10)
and 1% (1/100) v/v). A reduction in the S/N value (<0.8 cut-off) of
the luminescent signal of –S9 suspensions indicates cytotoxicity,
whereas a genotoxic effect is characterized by an increase (>1.5
cut-off) of the luminescent signal of +S9 suspensions. 4-
nitroquinoline-oxide (4-NQO) and benzo[a]pyrene (BaP) are used
as positive controls for Genox strain. BaP only turns genotoxic after
S9 metabolization (+S9).
2.3.2. Metabolic activity and live/dead cell viability assay
RHCIII-MPC and CLP-PEG hydrogels of 6 mm diameter were
placed into 96-well plates. Immortalized human corneal epithelial
cells (HCECs) [19] were seeded onto the surface of the materials at
a density of 9000 cells per hydrogel (n = 3). Cells seeded at similar
density on tissue culture plastic (TCP) served as a control. HCECs
were cultivated in keratinocyte serum-free medium (KSFM;
17005075, Thermo Fisher Scientific, MA, USA) in a humidified 37
C incubator for 4 days (96 h). At 24 h, 48 h, 72 h and 96 h of culti-
vation, a PrestoBlue cell metabolic activity assay (A13261, Thermo
Fisher Scientific) was performed according to the manufacturer’s
protocol. In brief, PrestoBlue was added to the cultures and incu-
bated for 60 min. The supernatant was transferred to a 96 well
plate and fluorescence was read at 590 nm using VICTOR3 plate
reader (Perkin Elmer, MA, USA). Finally, cultures were rinsed 1
with preheated KSFM to remove excess PrestoBlue, after which
the cultures were further cultivated in KSFM. Supplementary
Live/Dead staining (L3224, Thermo-Fisher Scientific) was per-
formed at 48 h cultivation, where cells were double-stained with
calceinacetoxymethyl (Calcein AM) and ethidium homodimer-1(EthD-1). Cells cultured on TCP and treated with 0.1% Saponin for
30 min at 20 C were used as positive controls for the Live/Dead
assay. Independent non-parametric testing was performed using
the SPSS 21 Kruskal-Wallis test (IBM Corp, NY, USA) and Prism 5
(GraphPad software, CA, USA). P  .05 was considered significant.
2.4. Corneal implant surgery and clinical evaluation in mini-pigs
In preparation for clinical translation, in compliance with the
OECD Principle of Good Laboratory Practice (GLP), ENV/MC/CHEM
(98) 17, 1997, and with local ethical permission, one CLP-PEG or
RHCIII-MPC implant was grafted into the right cornea of each of
four Gottingen mini-pigs (Ellegaard, Denmark) per group by ante-
rior lamellar keratoplasty (ALK), at Adlego Biomedical AB (Solna,
Sweden). Two weeks before surgery the animals were given a thor-
ough clinical examination to establish a baseline for corneal health.
Animals were intubated and anaesthetized prior to surgery. The
right cornea of each pig cornea was cut with a 6.5 mm circular tre-
phine to a depth of 500 mm, and the corneal button was then man-
ually dissected with a diamond knife and removed. Hydrogel
implants were cut with 6.75 mm diameter trephine and placed into
the wound bed. A piece of 7 mm diameter clinical human amniotic
membrane (HAM) (St:Erik’s Eye Hospital, Stockholm) was placed
over the implant to suppress undesired inflammation and the
implants were kept in place with 10/0 nylon overlying sutures.
Upon completion of the surgery, an antibacterial and anti-
inflammatory ophthalmic suspension (Tobraonewith 3 mg/ml dex-
amethasone and 1 mg/ml tobramycine, Alcon, Sweden) was admin-
istered. The maintenance dose was 1 drop, 3 times daily for 5
weeks. The unoperated contralateral corneas served as controls.
The health status of all animals was monitored throughout the
12 months study. The corneas and implants were evaluated before
surgery, at 5 weeks and then at 3, 6, 9 and 12 months after surgery.
The examinations were performed by a surgeon who was blinded
to the specifications of the implants in individual animal. These
examinations consisted of slit lamp biomicroscopy (to evaluate
haze from a 0 to +4 scale, any neovascularization and general
health of the eye using modified MacDonald-Shadduck scoring sys-
tem [20], pachymetry to measure cornea/implant thickness
(Tomey SP 3000, Tomey, Inc., Japan), Schirmer’s tear test to evalu-
ate the extent of the tear film (tear strips from TearFlo, Hub Phar-
maceuticals, Rancho Cucamonga, CA, USA), intraocular pressure
(using a TonoVet tonometer, Icare Finland Oy, Vantaa, Finland),
esthesiometry to determine corneal sensitivity as a measure of
nerve function (using a Cochet-Bonnet esthesiometer; Handaya
Co., Tokyo, Japan) and in vivo confocal microscopy (Heidelberg
HRT3 with a Rostock Cornea Module, Heidelberg Engineering
GmbH, Dossenheim, Germany) to access in-growth of corneal cells,
nerves and any blood vessels or inflammatory cells.
2.5. Immunohistochemistry and immunocytochemistry
Samples of implanted and control unoperated corneas were
processed through a sucrose gradient for frozen sectioning. Seven
micron frozen sections mounted on glass slides were fixed with
cold methanol (10 min, 20 C), air dried, immersed in PBS and
then incubated with 5% goat serum (Cat. No. 0060-01, Southern
Biotech, Birmingham, AL) in Tris buffered saline (TBS) with 0.1%
saponin (incubation buffer) over night at 4 C. Subsequently, sec-
tions were incubated with a range of the primary antibodies
diluted with incubation buffer overnight at 4 C. The antibodies
tested are listed in Table S1.
After washing off residual primary antibodies with incubation
buffer, sections were incubated with the secondary antibodies
(goat anti-rabbit Alexa 488 or goat anti-mouse Alexa 488 or goat
anti-rabbit Alexa 594; Jackson Immuno Research Laboratories
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60 min at room temperature. After washing in TBS-T (TBS with
0.05% tween), the slides were dehydrated and mounted with Vec-
tashield mounting medium with DAPI (Vector Laboratories, Inc.,
Burlingame, CA) for cell nuclei visualization. Fluorescent images
were captured using an inverted LSM-800 Zeiss confocal micro-
scope (LSM800, Carl Zeiss Microscopy, Germany). Similar staining
procedure was performed for in vitro experiments using primary
HCEC out grown from the human corneal rim explants on the
respective hydrogels or TCP after fixation with 4% paraformalde-
hyde for 10 min and ice cold Methanol for 10 min at 20 C. This
study using cadaveric human corneal rim explants followed the
tenets of the Declaration of Helsinki and was approved by the
Antwerp University Hospital Ethical Committee (ethical committee
approval: 14/30/319).
To examine the extent of nerve regeneration within the
implants, whole mount staining was performed using anti-beta
III tubulin antibody. Freshly excised corneas were washed in
0.01 M PBS and fixed in 2% glutaraldehyde and 2% PFA in 0.1 M
phosphate buffer (PB) for 3 h, then washed three times in 0.01 M
PBS and stored at 4 C. Before the overnight incubation at 4 C with
the beta III tubulin antibody all specimens were rocked for 20 min
in 0.1 M Tris-buffered saline (TBS), mounted in 1% Paraformalde-
hyde solution for 30 min then washed with TBS, permeabilized
with 0.2% Triton X100 (Cat. No. X100, Sigma-Aldrich) in TBS and
then blocked for 4 h at room temperature in 4% heat-inactivated
fetal bovine serum (FBS) and 0.2% TritonX100 in 0.1 M TBS (block-
ing solution). Incubation with the secondary goat anti-mouse Alexa
488 antibody diluted 1:1000 with the blocking solution was car-
ried out for 4 h at 4 C. Finally, specimens were washed with 0.1
M TBS and mounted with DAPI. Pictures were taken using an
inverted confocal microscope.2.6. Transmission and scanning electron microscopy
The samples were processed for regular and ultra-low temper-
ature freezing TEM and SBF-SEM. For SBF-SEM, after fixation, sam-
ples of implanted corneas were cut into thin (<1 mm) slices to
preserve the positioning of the implant in relation to host cornea.
Each sample slice was transferred to 1.5% potassium ferri-
cyanide/1% osmium tetroxide in cacodylate buffer for 1 h and then
washed in distilled water. The samples were then placed sequen-
tially in 1% aqueous thiocarbohydrazide, 1% osmium tetroxide
and 1% aqueous uranyl acetate, each for 1 h. All the staining steps
were followed by 30 min distilled water washing steps. The sam-
ples were then incubated for 1 h in a solution of lead aspartate at
60 C. After staining, the corneal samples were washed in two
changes of distilled water for 30 mins. The specimens were then
dehydrated in an ethanol series from 70% through to 100% and
via propylene oxide infiltrated and embedded in CY212 (TAAB,
Berkshire, UK) epoxy resin and polymerized for 24 h at 60 C. The
surface of polymerized resin blocks were then trimmed and
attached to Gatan (PEP6590) specimen pins. The pins were then
gold coated and transferred to a Zeiss Sigma VP FEG SEM equipped
with a Gatan 3View2 system, where data sets of up to 1000 images
were acquired of the block surface every 100 nm through auto-
mated sectioning. Each image was acquired at 4 K X 4 K pixels, at
a pixel resolution 6.5 nm and a pixel dwell time of 8 ms. Using an
SEM accelerating voltage of 3.4 keV in low vacuum variable pres-
sure mode (28 Pa). Imaging data was acquired from a 26.5 mm 
26.5 mm region of interest. Selected serial image sequences were
extracted from the image data and 3D reconstructions were gener-
ated using Amira 6.0 software (FEI, ThermoFisher).
For conventional TEM, 110 nm ultrathin sections were taken
from the central region of the implant specimens prepared forSBF SEM using a Leica UC6 ultramicrotome. The ultrathin sections
were collected onto uncoated 300HEX grids.
For optimal structural preservation, RHCIII-MPC and CLP-PEG
biosynthetic constructs were processed for TEM using a high pres-
sure freezing technique using a Leica EMPACT2 high pressure free-
zer (Leica Microsystems GmbH, Vienna, Austria). Approximately 1.
5 mm  1.5 mm  150 mm of the RHCIII-MPC samples were dis-
sected out to fit into a Leica high-pressure freezer membrane car-
rier. Vitrified specimens were then freeze substituted at 80 C in
2% osmium/acetone, 1% tannic acid/acetone and 1% uranyl acetate/
acetone for 88 h using a Leica AFS2 freeze substitution device. The
samples were then embedded in Araldite resin at 60 C for 24 h.
Ultrathin sections (110 nm) were cut and then placed on 1 mm
peloform-coated slot grids.
For the visualization of sulphated PGs, the corneas which had
been pre-fixed in 2.5% glutaraldehyde/2% paraformaldehyde in
100 mM cacodylate buffer pH 7.2 were washed in 25 mM sodium
acetate buffer (pH 5.7) with 0.1 M magnesium chloride for 12 h on
a rotator. The corneal samples were then incubated in 0.05% cupro-
meronic blue in 25 mM sodium acetate buffer (pH 5.7) with 0.1 M
magnesium chloride for 12 h at 4 C. The corneal sampleswere then
briefly washed in buffer followed by 15 min incubations in aqueous
0.5% sodium tungstate, then 0.5% sodium tungstate in 50% ethanol,
to enhance the electron density of the PG-cupromeronic blue com-
plex. Specimens were dehydrated through an ascending ethanol
series before being embedded in Araldite resin and polymerized at
60 C for 24 h. Ultrathin sections (110 nm thick) were cut with a
diamond knife on a Leica Ultracut UC6 ultramicrotome. Sections
were collected on uncoated 300HEX copper grids, stained with sat-
urated aqueous uranyl acetate for 30 min at room temperature. All
specimens were examined in a JEOL 1010 TEM (Jeol (UK) Ltd.) at an
accelerating voltage of 80KV fitted with an 11-megapixel 14-bit
Orius SC 1000 CCD TEM camera (Gatan, Pleasanton, CA).2.7. Statistical analyses
Data in table and graphs are reported as means ± SD. Statistical
analyses performed for each test is noted in the relevant section.
Statistical significance was set at P  0.05.3. Results
3.1. CLP-PEG and RHCIII-MPC hydrogels
Both control RHCIII-MPC implants (Fig. 1a) and CLP-PEG
implants (Fig. 1b) were optically clear, with over 90% light trans-
mission, exceeding that of the human cornea [21] and a refractive
index that approximates that of the human cornea [22]
(Table S2A). High pressure freezing transmission electron micro-
scopy (TEM) showed that both hydrogels comprised very fine fib-
rils (Fig. 1c, d). The denaturation temperature of the CLP-PEG
hydrogels was considerably higher than those of native corneas
and RHCIII-MPC controls (Table S2A). However, this likely reflects
the temperature at which PEG and not the peptides start to melt.
RHCIII-MPC implants had considerably higher tensile strength,
but CLP-PEG implants were more elastic and showed 4 times the
% elongation, compensating for the lower strength during surgical
handling (Table S2B). Both implants were significantly weaker than
human corneas, but this can be accounted for by the difference in
solids content. Implants comprised of well over 90% water while
the human cornea contains about 78% water [23].
The CLP-PEG hydrogels were stable in storage for over 12
months at 4 C, showing no to minimal differences in optical trans-
parency, water content and flexibility (Table S2). Their collagenase
degradation profile (Fig. S1A) was similar to that previously
Fig. 1. Implants, structure and mechanical stability. Control RHCIII-MPC implants (a) and CLP-PEG implants (b) are both optically clear as 500 lm thick corneal shaped
implants. Similarly, mimicking RHCIII-MPC implants (c) CLP-PEG implants (d) display a nanofibrillar structure when observed using high pressure freezing TEM imaging.
Scale bars, 200 nm. Oscillatory rheology of CLP-hydrogels pre- and post-grafting into rabbit corneas compared to healthy, unoperated rabbit corneas. (e) Storage modulus, (f)
Loss modulus and (g) Loss tangent as a function of oscillation frequency at 0.27% shear strain amplitude.
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(Table S3, Fig. S1B) between freshly made samples and stored sam-
ples shows the presence of all characteristic amide absorption
peaks relevant to CLP and are in good agreement with earlier stud-
ies [17,24]: amides A (3300 cm1), B (3080 cm1), I (1660
cm1) and II (1500 cm1).
Importantly, CLP-PEG implants grafted into rabbit corneas
became stably integrated by six months post-operation. Oscillatory
rheology of CLP-PEG hydrogels showed that the storage modulus
values of the implants were much higher than those of the rabbit
corneas, indicating higher stiffness and lower compliance of the
implants (Fig. 1e and f). On the contrary, healthy unoperated rabbit
corneas were compliant and extremely tear resistant, with a higher
loss tangent, correlating with the damping behavior of a viscoelas-
tic material (Fig. 1 g). The regenerated neo-corneas had mechanical
properties similar to those of the healthy naive rabbit corneas
(Fig. 1e–g).
3.2. In vitro toxicology and biocompatibility evaluation
In vitro cytotoxicity and genotoxicity assessments were per-
formed using the VitotoxTM protocol (Gentaur, Belgium), a highly
sensitive technique that is closely related to the Ames test. In this
test, two different strains of Salmonella typhimurium used respec-
tively for cytotoxicity and genotoxicity testing were exposed to dif-
ferent dilutions of homogenized hydrogels, along with positive
controls [25]. Neither the RHCIII-MPC controls (Fig. 2a) nor CLP-
PEG gels (Fig. 2b) were cytotoxic or genotoxic. PrestoBlue Cell Via-
bility reagent used to assess viability and proliferation showed that
therewas no statistically significant difference (P > .05) inmetabolic
activity of human corneal epithelial cells (HCECs) seeded on CLP-
PEG or RHCIII-MPC hydrogels (Fig. 2c). The only difference observed
was between cells grown on the three-dimensional hydrogels and
those grown on two-dimensional tissue culture plastic (TCP) (Fig.
2c). The metabolic activity of cells on TCP was significantly higher
at 24 h and 48 h indicating a larger cell number. However, by 72 h
and 96 h, there were no differences observed amongst all tested
conditions (Fig 2c). These results were confirmed by a supplemen-
tary Live/Dead analysis performed at 48 h post-culture, showing
minimal cell death on the hydrogels and TCP substrates (Fig. 2d).3.3. Implantation and clinical evaluation
Both control RHCIII-MPC and CLP-PEG implants were seam-
lessly incorporated into the mini-pig corneas without any exces-
sive redness, swelling or inflammation. The rate and course of
regeneration stimulated by CLP-PEG implants paralleled that of
control RHCIII-MPC implants over the 12-month observation per-
iod (Table 1), resulting in neo-corneas of comparable thickness
(Fig. S2). At 12 months post-operation, all regenerated neo-
corneas remained stably integrated and were optically transparent
(Fig. 3a) without any sustained immune suppression. In general,
implanted corneas showed early vascular in-growth at three
months post-operation, which was coincidental with the develop-
ment of haze in the grafted eyes. The vessels receded and the
implanted corneas became clear again. In vivo confocal microscopy
showed that all implanted corneas had regenerated epithelia sim-
ilar to healthy unoperated corneas. Infiltration of stromal cells was
observed at three months post-operation (Fig. S3). The corneal
nerves that were cut during the surgery had regenerated and were
observed penetrating the implant area at six months post-
operation (Fig. S3). By 12 months post-operation, the regenerated
neo-corneas had fully regenerated epithelia (Fig. 3b), a populated
stroma (Fig. 3c) and corneal nerves (Fig. 3d) resembling those of
their normal, unoperated contralateral counterparts. Aesthesiome-
try measures corneal sensory function and hence, provides an indi-
cator of nerve regeneration. At five weeks post-operation, the
corneas were unresponsive to touch (Fig. 3e). At three months
post-operation, CLP-PEG implanted corneas were more touch sen-
sitive than RHCIII-MPC implanted ones. By six months post-
operation, however, touch sensitivity of all implanted corneas
was comparable to that of normal controls.3.4. Histology and immunohistochemistry
Histopathological examination of implanted corneas performed
in compliance with OECD GLP principles by a blinded vet patholo-
gist (BioVet AB, Sollentuna, Sweden) concluded that there was no
difference between CLP-PEG and RHCIII-MPC implanted corneas.
Epithelial hyperplasia was noted in all regenerated neo-corneas
Fig. 2. Biocompatibility of Implants. Neither RHCIII-MPC (a) nor CLP-PEG (b) homogenized hydrogels tested at dilutions of 10% (1/10 w/v) and 1% (1/100 w/v) showed any
noticeable trace of genotoxicity or cytotoxicity unlike the respective positive controls, BaP and 4NQO. A PrestoBlue assay (c) showed that proliferation rates of human corneal
epithelial cells on RHCIII-MPC and CLP-PEG hydrogels were similar. Live/dead assay further shows minimal cell death among the RHCIII-MPC and CLP-PEG like TCP control
(d). Scale bars, 100 mm. For a positive staining of Live/dead assay the TCP cultured cells are treated with 0.1% saponin for 30 min at 20 C.
Table 1
Progress of CLP-PEG and RHCIII-MPC implants grafted into corneas of mini-pigs, compared to untreated contralateral control eyes over the 12 month post-operation period.
Treatment Time Cornea thickness (mm) Haze Vascularization Schirmer’s tear test (mm) Aesthesiometry (mm) IOP (mmHg)
implant margin
CLP-PEG pre-op 706 ± 20 0 0 0 12 ± 3 3.9 ± 0.3 10 ± 1
1 m – 0.38 0.5 1.75 7 ± 1 0 –
3 m 690 ± 16 0.25 1.75 0 13 ± 3 1.3 ± 0.4 16 ± 2
6 m 702 ± 22 0 0 0.75 12 ± 1 3.4 ± 0.1 16 ± 2
9 m 724 ± 13 0 0 0.5 16 ± 2 2.9 ± 0.1 19 ± 8
12 m 747 ± 8 0 0 2 13 ± 4 3.4 ± 0.1 22 ± 2
RHCIII-MPC pre-op 704 ± 21 0 0 0 11 ± 3 4.4 ± 0.6 11 ± 1
1 m – 0.38 0.5 0.5 7 ± 2 0 –
3 m 652 ± 9 0.69 1.75 0.5 15 ± 2 0.4 ± 0.5 14 ± 2
6 m 669 ± 22 0 0 2 13 ± 2 4.4 ± 0.6 20 ± 2
9 m 687 ± 11 0 0 0 13 ± 4 4.4 ± 0.7 16 ± 2
12 m 693 ± 23 0 0 0 15 ± 4 4.4 ± 0.8 15 ± 1
Untreated pre-op 725 ± 11 0 0 0 8 ± 2 8 ± 2 11 ± 1
1 m – 0 0 0 9 ± 1 9 ± 1 –
3 m 730 ± 10 0 0 0 12 ± 2 12 ± 2 17 ± 2
6 m 738 ± 10 0 0 0 10 ± 1 10 ± 1 17 ± 3
9 m 747 ± 11 0 0 0 13 ± 3 13 ± 3 16 ± 6
12 m 767 ± 11 0 0 0 15 ± 2 15 ± 2 18 ± 2
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neas (Fig. 4a).
Both CLP-PEG and RHCIII-MPC regenerated neo-corneas had
cytokeratin 3-positive, fully differentiated epithelia, like un-
operated controls (Fig. 4b). The regenerated neo-cornea stromas
were positively stained for collagen type III (Fig. 4c) which co-
exists with type I within the stromal ECM [26], and type V (Fig.
4d), whichmakes up 10–20% of corneal collagen [27]. No blood ves-
sels (no CD31 staining) or lymphatic vessels (no LYVE1 staining)
were found within the regenerated neo-corneas or healthy controls
(Fig. S4). b-tubulin staining of whole mounts confirmed restoration
of parallel nerve fibres of the sub-epithelial nerve plexus in both
implant groups that resembled the unoperated controls (Fig. 4e).
TEM confirmed the similarity of epithelial cells of CLP-PEG and
RHCIII-MPC regenerated neo-corneas to those of the unoperatedcorneas but with hyperplasia (Fig. 4f). The underlying regenerated
stromas contained cells arranged in lamellae (Fig. 4 g). However,
the lamellae were less structured in the neo-corneas compared
to controls, and particularly in the CLP-PEG implanted corneas as
seen by serial block face-SEM (SBF-SEM) 3D reconstruction (Fig.
4h; Videos S1–3). Staining for proteoglycans below the newly
regenerated epithelium as visualised by TEM showed that their
arrangement within RHCIII-MPC and CLP-PEG was similar to the
arrangement in an unoperated mini pig cornea (Fig. 4i).
3.5. Implant – host interactions
Ultrastructural analysis of CLP-PEG hydrogel-implanted corneas
showed that vast quantities of extracellular vesicles (EVs) were
secreted from the regenerated corneal epithelium (Fig. 5a, Fig. S5,
Fig. 3. RHCIII-MPC and CLP-PEG corneal implants and their performance in mini-pigs. Examples of optically clear RHCIII-MPC and CLP-PEG hydrogel implants (a). After 12
months of implantation in corneas of mini-pigs, the implants remain clear like the unoperated cornea. Arrows indicate the boundaries of the implants. In vivo confocal
microscopy shows that both RHCIII-MPC and CLP-PEG implanted corneas have regenerated their epithelium (b), stroma (c) and sub-epithelial nerve plexus (d) to resemble
their counterparts in the normal, healthy cornea. Scale bars, 150 mm. Aesthesiometry measures the pressure needed to obtain a blink reaction, i.e. touch sensitivity, which is
correlated to nerve function. Pre-operatively, all healthy corneas showed a response to light touch. At 5 weeks post-operation, the implanted corneas were non-responsive,
even with maximal pressure exerted. At 3 months, touch sensitivity is returning so less pressure was needed for a response. By 6 months, sensitivity was back to normal
levels. * – p < .05 as compared to un-operated eyes (Kruskal-Wallis test with Bonferroni post hoc test).
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Fig. 4. Characterization of regenerated neo-corneas. (a) H&E sections through a healthy, unoperated cornea, and regenerated neo-corneas at 12 months after implantation
with control RHCIII-MPC and CLP-PEG scaffolds. Epithelial hyperplasia was noted in the implanted corneas, which is normal in post-grafting tissues (b). Scale bars, 100 mm.
The regenerated corneal epithelium shows staining with cytokeratin 3/12, a marker of differentiated cells in all three samples. Stromal collagens types III (c) and V (d) are
present in the implanted as well as unoperated corneas, showing in particular that remodeling and extracellular matrix production is occurring in CLP-PEG implants that
contained no collagen. Sub-epithelial nerve plexus stained with b-tubulin (e) showing nerve regeneration in CLP-PEG hydrogels as in control RHCIII-MPC and unoperated
contralateral eyes. Scale bars, 100 mm. At the ultrastructural level, TEM micrographs of all three samples show an epithelium with distinct layers of elongated, cuboidal and
flattened cells, characteristic of healthy corneas (f). Scale bar, 50 mm. TEM images show a regular, lamellar arrangement in both unoperated and regenerated stromas (g). Scale
bar, 20 mm. The CLP-PEG neo-corneas have slightly less regular stromas as seen in 3D reconstructed SBF-SEM images (epithelium rendered in blue) (h) suggesting an on-going
process. Both neo-corneas contained collagen fibrils decorated with proteoglycans (i), similar to the matrix of the healthy, unoperated cornea. Scale bar, 200 nm.
J.R. Jangamreddy et al. / Acta Biomaterialia 69 (2018) 120–130 127Video S4). Immunohistochemistry performed on frozen sections of
pig corneas implanted with CLP-PEG or RHCIII-MPC showed differ-
ential staining for CD9, a well-known marker for exosomes, and
Rab-7, a endosome-exosome marker [28]. Healthy unoperated cor-
neas and RHCIII-MPC implanted corneas showed minimal to mod-
erate staining for CD9 while CLP-PEG implanted corneas showed
marked CD9 staining (Fig. 5b and c). Rab7 staining was increased
in the epithelial layer of CLP-PEG implanted corneas relative to
unoperated controls (Fig. 5d). In RHCIII-MPC implants, Rab7 stain-
ing was confined to the basal portions of the epithelium. We con-
firmed that HCECs were producing EVs by culturing these cells on
CLP-PEG hydrogels. Controls comprised RHCIII-MPC hydrogels and
tissue culture plastic (Fig. S6). HCECs on tissue culture plastic
showed CD9 staining mainly at the leading edges. CD9 stained
vesicles were seen over the entire cytoplasm of cells grown on
RHCIII-MPC, while staining in cells on CLP-PEG were mainly perin-
uclear (Fig. S5). Rab7 stained vesicles remained intracellular and
were markedly increased in HCECs cultured on CLP-PEG, compared
to RHCIII-MPC, while staining was perinuclear on tissue culture
plastic (Fig. S6). Finally, we observed increased CD9 staining below
the basal epithelium of the limbus showing co-localization with
collagen type V in the CLP-PEG implanted corneas but neither
RHCIII-MPC nor unoperated corneas showed such striking co-
localization (Fig. 5e).
4. Discussion
A wide range of mimetic peptides have been developed as ana-
logs to native collagen. The Hartgerink group produced the firstcollagen mimetic peptides that formed hydrogels from purely pep-
tide interactions suggesting their possible functional equivalence
to full-length collagen [29]. However, these hydrogels as described
were too soft to be used as corneal implants. By conjugating CLP to
inert PEG [2,4], we produced implants that were sufficiently robust
for surgical handling [4]. This is keeping with reports where several
backbone structures such as poly(amidoamine)-based dendrimers
(PAMAM), 4 arm or 8 arm poly ethylene glycol (PEG) when conju-
gated to CLPs, which not only promoted triple helical formation of
the attached CLPs but also provided additional mechanical
strength [2]. CLP-PEG hydrogels were optically transparent and
flexible, and retained their optical clarity and flexibility after 12
months of storage. Their composition remained unchanged as evi-
denced by the FTIR spectral profiles of freshly-made and 30-month
old hydrogel samples. Although the Amide I absorption peak (pri-
marily peptide bond C = O stretch) is known to be highly depen-
dent on peptide secondary structure [24,30], the appearance of
this very characteristic peak along with the others, namely Amide
A, B, and II (Table S3, Fig. S1B), attributed to the presence of CLP
which are also in good agreement with previously published
reports [17,24], and the striking similarity in the fingerprint region
(800 cm1) between the fresh and the stored sample indicate that
their chemical composition remained essentially the same. We also
showed that the ability of hydrogels to resist collagenase digestion
was unchanged after 30 months of storage compared to the profile
reported for freshly-made samples [4]. It is pertinent to note, how-
ever, that while FTIR and collagenase digestion assays are useful
techniques to monitor the stability of the hydrogels, for a complete
assessment of long-term storage, complementary methods (such
Fig. 5. Extracellular vesicle release from regenerating neo-corneas stimulated by biomimetic implants. (a) 3D reconstructed serial block face scanning electron micrographs
of an unoperated healthy cornea and regenerating neo-corneas at 12 months after implantation with control RHCIII-MPC or CLP-PEG, showing the release of extracellular
vesicles (rendered in gold) from the lower epithelial layers into the stroma. (b) Immunofluorescent micrographs of exosome marker CD-9 stained cornea samples. (c)
Corresponding 3D reconstructions of CD9-stained sections confirm that the extracellular vesicles released by the epithelium include positively-stained exosomes. (d) Rab7
stained endosomes-exosomes in both unoperated and implanted corneas. Cell nuclei are counterstained blue with DAPI. Scale bars, 25 mm.
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curves, surface changes using SEM, contact angle and analysis of
degradation solutions, etc.) would be necessary [31,32]. Neverthe-
less, our results indicated that CLP-PEG hydrogels remained suffi-
ciently stable when stored for over 12 months. They were not as
tough as the clinically evaluated RHCIII-MPC implants, but com-
pensated for this by being more elastic, which allowed them to
withstand the grafting procedure. Implants into rabbit corneas
showed that the mechanical properties of the regenerated neo-
corneas were similar to healthy, unoperated corneas. This is the
desired end-point, so initially weaker implants were not an issue.
Prior to pre-clinical use, a range of in vitro toxicology tests is
required to demonstrate the safety of the implants. Like RHCIII-
MPC implants that have been tested in animals [33] and clinically
[7,9], CLP-PEG implants were cell friendly and allowed for prolifer-
ation. Genotoxicity tests results showed little/no risk of induction
of mutagenesis.
Unlike RHCIII-MPC implants, however, CLP-PEG implants do not
contain any collagen. Remarkably, high pressure freezing TEM
showed that CLP-PEG hydrogels had very fine fibrillar structures
similar to those of the RHCIII-MPC hydrogels. This supports the
contention that CLPs mimic their native counterparts in forming
tiny fibrils [34].
When grafted into pig corneas, like the control RHCIII-MPC
implants, CLP-PEG implants promoted regeneration of corneal
epithelium, stroma and nerves [4]. Here, detailed histopathological
examination showed hyperplasia of the epithelium in implanted
corneas. The implants were only 500 lm thick while the pigs’ cor-
neas were all over 600 lm, showing that the epithelium had thick-
ened to restore normal corneal thickness. This is a well-knownpost-surgical finding in human and animal corneas after photore-
fractive surgery [35,36] and after corneal implantation [37], so
was not considered a pathological finding.
In Islam et al., we reported the presence of type I and V collagen
in regenerated neo-corneas implanted with CLP-PEG [4]. In the cor-
nea, as with the rest of the body, the cells most frequently associ-
ated with synthesis and secretion of collagen are the fibroblasts
and their precursors, although there were early reports that the
corneal epithelium secretes collagen [38,39]. In this study, SBF-
SEM clearly showed that the regenerating epithelium produced
copious amounts of EVs. Immunohistochemistry showed co-
localization of exosome marker CD9 with collagen-type V to these
EVs and adjacent area. This strongly suggested that cornea-specific
collagen V was secreted by the epithelium into the stroma through
EVs. TEM showed that proteoglycans were present. During early
cornea development, the epithelium produces ECM that attracts
stromal cells. Taken together, our results strongly suggest that this
process is recapitulated in the biomaterials-induced corneal regen-
eration observed, and EV secretion is involved. The regenerated
epithelium had most likely secreted collagen and proteoglycans
within the implants, thereby attracting in-growth of fibroblasts
and nerves. Consistent with this hypothesis is the fact that mark-
edly more exosomes are secreted by epithelium in CLP-PEG
implanted corneas that contain no collagen that in control
RHCIII-MPC implants where collagen is already present within
the scaffolds. While further work is ongoing to characterize the
EVs produced by CLP-PEG and RHCIII-MPC implantation, we have
nevertheless shown that EVs have a role in collagen- and analog-
enabled corneal regeneration. This is in keeping with observations
that exosomes are potent mediators of regeneration that are now
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including cardiac regeneration [40].
Studies of nerve regeneration showed that corneas implanted
with CLP-PEG regained sensitivity slightly faster. However, by six
months post-operation, touch sensitivity which is correlated to
nerve function was equivalent in both CLP-PEG and control
RHCIII-MPC eyes.5. Conclusion
As peptide analogs of ECM proteins head towards clinical appli-
cation, establishing their safety and efficacy profiles is critical. We
have shown that hydrogels made from a short collagen analog con-
jugated to PEG are safe and functionally equivalent to those com-
prising full-length, recombinantly produced human collagen that
successfully regenerated human corneas, in both in vitro and
in vivo pre-clinical animal testing. We further show that these
ECM-mimetic hydrogels promoted regeneration by stimulating
in-growing endogenous host cells to produce matrix components
through secretory extracellular vesicles. With this safety and effi-
cacy profile and mechanism of action now known, further testing
of CLP-PEG hydrogels in human subjects is merited to determine
the full extent of the utility of peptide analogs as pro-
regeneration implants in the cornea and in other organ systems.Acknowledgments
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